**Author details**

Zhaoping Liu\*, Andrea Gomez-Donart, Caroline Weldon, Nina Senutovitch and John O'Rourke iQue® Sartorius, Albuquerque, NM, USA

\*Address all correspondence to: zhaoping.liu@Sartorius.com

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Developing a Novel Multiplexed Immune Assay Platform to Screen Kinase Modulators… DOI: http://dx.doi.org/10.5772/intechopen.97304*

### **References**

[1] Medicines in Development for Autoimmune Diseases. *Pharmaceutical Research and Manufacturers of America* (PhRMA) 2016.

[2] Tang J, Pearce L, Odonnell-Tormey J, Hubbard-Lucey VM. Trends in the Global Immuno-Oncology Landscape. Nat. Rev. Drug Discov. 2018:17:912–922. DOI: 10.1038/nrd.2018.167

[3] Hosokawa K, Muranski P, Feng X, Townsley DM, Liu B, Knickelbein J, Keyvanfar K, Dumitriu B, Ito S, Kajigaya S, Taylor JG 6th, Kaplan MJ, Nussenblatt RB, Barrett AJ, O'Shea J, Young NS. Memory Stem T Cells in Autoimmune Disease: High Frequency of Circulating CD8+ Memory Stem Cells in Acquired Aplastic Anemia. J Immunol. 2016 Feb 15;196(4):1568–78. DOI: 10.4049/jimmunol.1501739

[4] Schmidt RE, Grimbacher B, Witte T. Autoimmunity and primary immunodeficiency: two sides of the same coin? Nat Rev Rheumatol. 2017 Dec 19;14(1):7–18. DOI: 10.1038/ nrrheum.2017.198

[5] Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 2015 Jul;74(1):5–17. DOI: 10.1016/j. cyto.2014.09.011

[6] Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015 Apr 3;348(6230):56–61. DOI: 10.1126/science.aaa8172

[7] Thakur A, Huang M, Lum LG. Bispecific antibody based therapeutics: Strengths and challenges. Blood Rev. 2018 Jul;32(4):339–347. DOI: 10.1016/j. blre.2018.02.004

[8] Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, Gartner J, Jia L, Trebska-McGowan K, Somerville RP, Robbins PF, Rosenberg SA, Goff SL, Feldman SA. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018 Jun;24(6):724– 730. DOI: 10.1038/s41591-018-0040-8

[9] June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018 Mar 23;359(6382): 1361–1365. DOI: 10.1126/science.aar6711

[10] Almåsbak H, Aarvak T, Vemuri MC. CAR T Cell Therapy: A Game Changer in Cancer Treatment. J Immunol Res. 2016;2016:5474602. DOI: 10.1155/2016/ 5474602

[11] Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology combinations: a review of clinical experience and future prospects. Clin Cancer Res. 2014 Dec 15; 20(24):6258–68. DOI: 10.1158/ 1078-0432.CCR-14-1457

[12] Navarro MN, Cantrell DA. Serinethreonine kinases in TCR signaling. Nat Immunol. 2014 Sep;15(9):808–14. DOI: 10.1038/ni.2941

[13] Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018 May;17(5):353–377. DOI: 10.1038/nrd.2018.21

[14] Frémin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol. 2010 Feb 11;3:8. DOI: 10.1186/1756-8722-3-8

[15] Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HPV. Kinasetargeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018 Feb 19;17(1):48. DOI: 10.1186/s12943-018-0804-2

[16] Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. J Clin Invest. 2015 May;125(5):1780–9. DOI: 10.1172/JCI76094

[17] Carnevalli LS, Sinclair C, Taylor MA, Gutierrez PM, Langdon S, Coenen-Stass AML, Mooney L, Hughes A, Jarvis L, Staniszewska A, Crafter C, Sidders B, Hardaker E, Hudson K, Barry ST. PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ Tcell activity. J Immunother Cancer. 2018 Dec 27;6(1):158. DOI: 10.1186/ s40425-018-0457-0

[18] Abril-Rodriguez, G., Torrejon, D.Y., Liu, W. *et al.* PAK4 inhibition improves PD-1 blockade immunotherapy. *Nat Cancer* **1,** 46–58 (2020). DOI.org/ 10.1038/s43018-019-0003-0

[19] Ding M, Kaspersson K, Murray D, Bardelle C. High-throughput flow cytometry for drug discovery: principles, applications, and case studies. Drug Discov Today. 2017 Dec; 22(12):1844–1850. DOI: 10.1016/j. drudis.2017.09.005

[20] Sklar LA, Carter MB, Edwards BS. Flow cytometry for drug discovery, receptor pharmacology and highthroughput screening. Curr Opin Pharmacol. 2007 Oct;7(5):527–34. DOI: 10.1016/j.coph.2007.06.006

[21] Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion. Immunology. 2010 Apr;129 (4):474–81. DOI: 10.1111/ j.1365-2567.2010.03255

[22] Martinez EM, Klebanoff SD, Secrest S, Romain G, Haile ST, Emtage PCR, Gilbert AE. High-Throughput Flow Cytometric Method for the Simultaneous Measurement of CAR-T Cell Characterization and Cytotoxicity against Solid Tumor Cell Lines. SLAS Discov. 2018 Aug;23(7):

603–612. DOI: 10.1177/ 2472555218768745

[23] Chen EW, Brzostek J, Gascoigne NRJ, Rybakin V. Development of a screening strategy for new modulators of T cell receptor signaling and T cell activation. Sci Rep. 2018 Jul 3;8(1):10046. DOI: 10.1038/s41598-018-28106-5

[24] Knapp S. New opportunities for kinase drug repurposing and target discovery. Br J Cancer. 2018 Apr;118(7): 936–937. DOI: 10.1038/s41416-018- 0045-6

[25] Saibil SD, Ohashi PS. Targeting T cell activation in immuno-oncology. Curr Oncol. 2020 Apr;27(Suppl 2): S98- S105. doi: 10.3747/co.27.5285. Epub 2020 Apr 1. PMID: 32368179; PMCID: PMC7193998.

[26] Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 2017 Feb 9;168 (4):707–723. doi: 10.106/j. cell.2017.01.017. PMID: 28187290; PMCID: PMCID: PMC5391692.

[27] Wang Y, Zhang K, Georgiev P, Wells S, Xu H, Lacey BM, Xu Z, Laskey J, Mcleod R, Methot JL, Bittinger M, Pasternak A, Ranganth S. Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function. PLoS One. 2020 Dec 3;15(12):e0243145. doi: 10.1371/journal.pone.0243145. PMID: 33270695; PMCID: PMC7714195.

[28] Zheng HY, Xu M, Yang CX, Tian RR, Zhang M, Li JJ, Wang XC, Ding ZL, Li GM, Li XL, He YQ, Dong XQ, Yao YG, Zheng YT. Longitudinal transcriptome analyses show robust T cell immunity during recovery from COVID-19. Signal Transduct Target Ther. 2020 Dec 24;5(1):294. doi: 10.1038/ s41392-020-00457-4. PMID: 33361761; PMCID:PMC7758413.

*Developing a Novel Multiplexed Immune Assay Platform to Screen Kinase Modulators… DOI: http://dx.doi.org/10.5772/intechopen.97304*

[29] Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman AR, Agyekum RS, Mathew D, Baxter AE, Vella LA, Kuthuru O, Apostolidis SA, Bershaw L, Dougherty J, Greenplate AR, Pattekar A, Kim J, Han N, Gouma S, Weirick ME, Arevalo CP, Bolton MJ, Goodwin EC, Anderson EM, Hensley SE, Jones TK, Mangalmurti NS, Luning Prak ET, Wherry EJ, Meyer NJ, Betts MR. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol. 2020 Jul 15;5 (49):eabd7114. doi: 10.1126/sciimmunol. abd7114. PMID:32669287; PMCID: PMC7402634.

*Edited by Shailendra K. Saxena*

The book focuses on various aspects and properties of high-throughput screening (HTS), which is of great importance in the development of novel drugs to treat communicable and non-communicable diseases. Chapters in this volume discuss HTS methodologies, resources, and technologies and highlight the significance of HTS in personalized and precision medicine.

Published in London, UK © 2022 IntechOpen © SARINYAPINNGAM / iStock

High-Throughput Screening for Drug Discovery

High-Throughput Screening

for Drug Discovery

*Edited by Shailendra K. Saxena*